Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care

Trial Profile

Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs BVAC C (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Cellid Company
  • Most Recent Events

    • 29 Jan 2018 Planned End Date changed from 1 Aug 2017 to 1 Aug 2020.
    • 29 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top